drug development

ENA Respiratory is a clinical-stage pharmaceutical company headquartered in Melbourne, Australia, with operations in the USA. It develops antiviral host defense enhancers for the prevention of severe complications from respiratory viral infections in vulnerable populations. Its lead product is INNA-051, a first-in-class TLR2/6 agonist developed as a self-administered nasal product with a weekly dosing regimen. The company was formed in 2020 as a spin-off from ENA Therapeutics Pty Ltd.

clinical-stage pharmaceutical developmentclinical trials

Epigen Biosciences is a pharmaceutical company discovering innovative, proprietary drugs to address unmet medical needs. It develops small-molecule compounds including an LPA1 receptor antagonist, selective sigma-1 receptor ligands, p70 S6 kinase inhibitors, and PAM-IIs, targeting conditions such as diabetic kidney disease, NASH/MASH, idiopathic pulmonary fibrosis, Alzheimer's disease, ALS, Fragile X syndrome, and stroke. The company combines medicinal chemistry and drug development expertise with academic collaborations.

ADME property assessmentcomputational designfocused library synthesishit-to-lead and lead optimizationin silico drug discoverymedicinal chemistryscaffold-hoppingscreeningstrategic project management

EpiVario Inc. is an innovation-focused biotechnology company spun out of the Epigenetics Institute of the University of Pennsylvania. It develops neuroepigenetic modulators and pharmacotherapeutics targeting a newly discovered epigenetic process in long-term memory, aiming to treat memory-related addiction and psychiatric disorders including PTSD, opioid use disorder, alcohol use disorder, and nicotine use disorder. Its cofounders discovered the metabolic enzyme ACSS2, and the company is developing a proprietary small molecule inhibitor of ACSS2.

epigenetic therapeutics researchsmall molecule inhibitor development

Epoulosis Therapeutics is a biotech company focused on the development and commercialization of novel therapeutics to treat diabetic complications such as diabetic foot ulcers and diabetic neuropathy. Its pipeline includes EPO-01, and it seeks strategic collaborations including in-licensing and co-development partnerships.

commercialization of novel therapeuticsdrug discovery

ePurines, Inc. is a drug development company focused on innovative purinergic-based therapies for obesity, metabolic syndrome, renal and liver diseases. The core technologies were developed in VA laboratories, patented by the U.S. Department of Veterans Affairs, and licensed to ePurines. The company leverages its purinergic signaling platform and expertise to target diseases affecting U.S. Veterans and the general population.

purinergic signaling platform

Espervita Therapeutics is focused on the discovery of metabolic reprogramming therapies, with a lead program developing first-in-class liver- and kidney-specific acetyl-CoA metabolic enzyme inhibitors. Its lead compound, EVT0185, is a first-in-class, liver- and kidney-selective inhibitor of acetyl-CoA metabolic enzymes that demonstrates broad efficacy in preclinical models—lowering blood glucose and lipid synthesis, reversing MASH and liver fibrosis, preserving kidney function, and decreasing HCC tumor burden. The company is led by a team with deep exper

drug discoveryin vivo and translational studiespreclinical studies

ExesaLibero Pharma, Inc is dedicated to developing new small molecule drugs to treat bone disease. Its primary mission is to complete preclinical toxicology and efficacy studies for a small-molecule drug aimed at controlling bone erosion in diseases such as rheumatoid arthritis, multiple myeloma, diabetes, periodontal disease, and tuberculosis, with results forming the basis for an Investigative New Drug (IND) application to the FDA.

pharmacokinetic and toxicokinetic testingpreclinical toxicology and efficacy studies

Faeth Therapeutics is a clinical-stage oncology company pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway. Its lead candidate PIKTOR is an all-oral combination designed to inhibit PI3K-alpha, mTORC1, and mTORC2 simultaneously. The company was founded in 2019 and in February 2026 was acquired by Sensei Biotherapeutics, making PIKTOR the combined company's lead program.

clinical trialspreclinical research

FarmPharma AB is a subsidiary of Double Bond Pharmaceutical that operates in the development and distribution of veterinary products. Its products are interferon-based therapies intended to both treat and prevent viral and bacterial infections in livestock while reducing the use of antibiotics.

development and distribution of veterinary products

Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system. Its lead asset bexmarilimab is a first-in-class anti-Clever-1 antibody being investigated in Phase I/II clinical trials for hematological cancers and solid tumors.

clinical trialsimmunotherapy researchpreclinical development

Fedora Pharmaceuticals Inc. is a Canadian clinical-stage biotechnology company based in Edmonton, Alberta, founded in 2011. It discovers and develops novel antibacterial therapies to combat antimicrobial resistance (AMR). Its pipeline includes nacubactam, a β-lactamase inhibitor/enhancer, and FPI-2119, a first-in-class non-β-lactam penicillin-binding protein inhibitor. The company's team also discovered tazobactam.

antibiotic discoverylicensingmedicinal chemistrypreclinical development

Fimbrion Therapeutics, Inc. is a St. Louis-based company whose mission is to discover, develop, and commercialize antimicrobial-sparing and -enabling drugs for the prevention and treatment of infectious diseases caused by bacteria, including drug-resistant strains. Its initial focus is an orally active drug to prevent and treat urinary tract infections (UTIs), targeting bacterial adhesins rather than bacterial viability.

commercializationdrug discovery

FLAG Therapeutics, Inc. is a near-term clinical stage company headquartered in Raleigh, North Carolina, focused on developing new small molecule therapeutics for difficult-to-treat cancers. Its lead candidate, FLAG-003, targets diffuse intrinsic pontine glioma (DIPG) and glioblastoma multiforme (GBM) and is projected to enter Phase 1/2 clinical development in early 2026 in children with DIPG. The company leverages three proprietary drug discovery platforms and holds an exclusive worldwide licensing agreement with Duquesne University.

computer modeling/artificial intelligence in drug discoverydrug discoverysmall-molecule therapeutics

Forta Bio is a private, California-based biotech developing ODC™ (Oligonucleotide-Dependent Cytotoxicity), a therapeutic class it created to selectively eliminate pathogenic cells while aiming to preserve healthy immunity. Built on foundational research at City of Hope and supported by multi-million-dollar grant funding, its platform spans oncology (FortaOnc™), autoimmune disease (FortaReg™), and aptamer-targeted delivery (FortaApt™), supported by its internal screening and optimization engine FortaGuideAI.

aptamer-targeted deliverygenerative multi-objective optimizationhigh throughput screeningin vivo studiesoligonucleotide therapeutics

Frontage Laboratories, Inc. is a global pharmaceutical development organization (PDO) and CRO providing integrated, science-driven product development services throughout the drug discovery and development process. It assists clients in advancing molecules through development to commercial launch, enabling innovators, generic, and consumer health companies to file IND, NDA, ANDA, BLA, and 505(b)(2) submissions in global markets.

analytical servicesbioanalysisbiostatisticscentral lab servicesclinical trial material manufacturingcommercial manufacturingDART servicesdata managementDMPKdrug discoveryformulation developmentgenetic toxicologyGMP routine testingmass spectrometrymethod development and validationsafety pharmacologystability programsstatistical programmingtoxicology

Gibson Oncology is a brain cancer drug development company in Miami, FL focused on glioblastoma therapies. It has begun a Phase II trial of LMP744 in glioblastoma, conducted by the NIH, in 40 patients who failed initial drug. LMP744 has c-Myc and Topo 1 activity, crosses the blood-brain barrier, has strong PDX data in GBM, and has FDA Orphan Drug Status. The FDA says the trial may qualify as a registration trial.

clinical trials

GoodCap Pharmaceuticals is a pharmaceutical company developing a multi-mechanism platform for neuroinflammation and brain health. Its lead candidate, GCAP001, is a dual-action neuroplastogen designed as a daily oral tablet to reduce inflammation and promote neural recovery. The company's first pivotal program targets PTSD, with a broader platform spanning depression, Parkinson's, and Alzheimer's.

pharmaceutical R&D

Hemispherian is a clinical-stage pharmaceutical company developing a novel class of small molecule drugs that target the TET2 enzyme as a targeted therapy for aggressive cancers. Its lead compound GLIX1 is entering clinical development for glioblastoma. The drugs work by restoring a cancer cell's normal epigenetic complement, triggering the DNA damage response and cancer cytotoxicity, and are well tolerated in normal tissues.

clinical-stage pharmaceutical research

Herantis Pharma Plc is a clinical-stage biotechnology company developing neurorestorative therapies aimed at slowing or stopping the progression of Parkinson's disease. Its lead product HER-096 is a CDNF-derived peptidomimetic targeting multiple Parkinson's disease mechanisms. The company is listed on Nasdaq First North Growth Market Finland under the ticker HRTIS.

biomarker researchclinical trials

A clinical-stage pharmaceutical company developing novel therapeutics designed to prevent and treat the toxic effects of heavy metal exposure on human health. The company is led by a world-class team of scientists and drug developers.

clinical-stage pharmaceutical development

of page Illumen Therapeutics is pursuing a moonshot in the treatment of aggressive cancers by increasing functional p53 with the development of PARN inhibitor drugs.Illumen Therapeutics is pioneering the development of first-in-class PARN inhibitor drugs that boost functional p53, the 'Guardian of the Genome,' to treat aggressive cancers and improve survival. Dysregulation of p53, a key tumor suppressor, is the hallmark of nearly all cancers, making drugging p53 the Holy Grail of cancer drug development. bottom of page

iNFixion Bioscience is a drug discovery company dedicated to developing drugs that treat and prevent the clinical manifestations of neurofibromatosis type 1 (NF1) for all patients, regardless of their specific genetic mutation. Its approach addresses the lack of functional NF1 protein (neurofibromin) by enhancing the body's ability to produce and maintain healthy neurofibromin, aiming to create a disease-modifying therapy that alleviates symptoms and prevents disease progression.

drug discovery

Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Guided by science and collective expertise, it works closely with patients to understand real-world challenges and develop meaningful solutions. Its therapies include ARIKAYCE and BRINSUPRI, and its areas of innovation include gene therapy with targeted delivery, protein deimmunization, RNA end-joining, and synthetic rescue.

clinical trialscommercializationgene therapy with targeted deliveryprotein deimmunizationresearchRNA end-joiningsynthetic rescue

iOnctura is a clinical-stage biotechnology company developing precision medicines for cancer and other challenging diseases. Founded in 2017, it develops high impact, low disruption therapies targeting the tumor-stroma-immune interface, focusing on neglected and hard to treat cancers with more effective, less toxic treatments.

clinical developmentoncology researchsmall molecule drug discovery